It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Adverse prognosis in Ewing sarcoma (ES) is associated with the presence of metastases, particularly in bone, tumor hypoxia and chromosomal instability (CIN). Yet, a mechanistic link between these factors remains unknown. We demonstrate that in ES, tumor hypoxia selectively exacerbates bone metastasis. This process is triggered by hypoxia-induced stimulation of the neuropeptide Y (NPY)/Y5 receptor (Y5R) pathway, which leads to RhoA over-activation and cytokinesis failure. These mitotic defects result in the formation of polyploid ES cells, the progeny of which exhibit high CIN, an ability to invade and colonize bone, and a resistance to chemotherapy. Blocking Y5R in hypoxic ES tumors prevents polyploidization and bone metastasis. Our findings provide evidence for the role of the hypoxia-inducible NPY/Y5R/RhoA axis in promoting genomic changes and subsequent osseous dissemination in ES, and suggest that targeting this pathway may prevent CIN and disease progression in ES and other cancers rich in NPY and Y5R.
Ewing sarcoma tumour cells frequently metastasize to the bone but the molecular mechanisms governing this process are not well understood. Here, the authors show that neuropeptide Y/Y5 receptor pathway is activated in the hypoxic tumour microenvironment, which results in cytokinesis defects and chromosomal instability, leading to bone invasion.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details


1 Georgetown University, Department of Physiology and Biophysics, Washington, United States (GRID:grid.213910.8) (ISNI:0000 0001 1955 1644); New York Genome Center, New York, United States (GRID:grid.429884.b) (ISNI:0000 0004 1791 0895)
2 Georgetown University Medical Center, Department of Biochemistry and Molecular & Cellular Biology, Washington, United States (GRID:grid.411667.3) (ISNI:0000 0001 2186 0438)
3 Georgetown University, Department of Human Science, School of Nursing and Health Studies, Washington, United States (GRID:grid.213910.8) (ISNI:0000 0001 1955 1644)
4 Georgetown University Medical Center, Department of Biochemistry and Molecular & Cellular Biology, Washington, United States (GRID:grid.411667.3) (ISNI:0000 0001 2186 0438); King Abdullah International Medical Research Center, Cell Therapy and Cancer Research Department, Riyadh, Saudi Arabia (GRID:grid.452607.2) (ISNI:0000 0004 0580 0891); King Saud bin Abdulaziz University for Health Sciences, Riyadh, Saudi Arabia (GRID:grid.412149.b) (ISNI:0000 0004 0608 0662)
5 Georgetown University Medical Center, Department of Oncology, Lombardi Comprehensive Cancer Center, Washington, United States (GRID:grid.411667.3) (ISNI:0000 0001 2186 0438); Georgetown University Medical Center, Center for Translational Imaging, Washington, United States (GRID:grid.411667.3) (ISNI:0000 0001 2186 0438)
6 Georgetown University, Department of Biostatistics, Bioinformatics and Biomathematics, Washington, United States (GRID:grid.213910.8) (ISNI:0000 0001 1955 1644)
7 University of Illinois, Genome Editing Core, Chicago, United States (GRID:grid.185648.6) (ISNI:0000 0001 2175 0319)
8 National Institutes of Health, Laboratory of Pathology, National Cancer Institute, Bethesda, United States (GRID:grid.94365.3d) (ISNI:0000 0001 2297 5165)
9 Georgetown University Medical Center, Department of Oncology, Lombardi Comprehensive Cancer Center, Washington, United States (GRID:grid.411667.3) (ISNI:0000 0001 2186 0438)
10 Georgetown University Medical Center, Center for Cell Reprogramming, Washington DC, United States (GRID:grid.411667.3) (ISNI:0000 0001 2186 0438)
11 Medical University of Gdańsk, Department of Pathology and Neuropathology, Gdańsk, Poland (GRID:grid.11451.30) (ISNI:0000 0001 0531 3426)
12 Georgetown University Medical Center, Department of Oncology, Lombardi Comprehensive Cancer Center, Washington, United States (GRID:grid.411667.3) (ISNI:0000 0001 2186 0438); Faculdades Pequeno Príncipe, Research Institute Pelé Pequeno Príncipe, Curitiba, Brazil (GRID:grid.411667.3)